NeuroPace reports sees Q4 revenue $21M-$21.5M, consensus $20.91M

“Throughout 2024, our entire team did an excellent job of executing on our strategy, resulting in 2024 revenue growth of more than 20%, strong gross margin performance, and continued operating discipline as evidenced by our reduced cash burn, while also making investments in our business that will support long-term growth,” said Joel Becker, NeuroPace (NPCE) president and CEO. “We remain focused on the execution of our three-part growth strategy to expand access to and adoption of RNS therapy.”